BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 235 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 0.62 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $16,928 | -0.2% | 2,390,948 | -0.8% | 0.05% | -1.9% |
| Q2 2023 | $16,968 | -29.5% | 2,410,190 | -16.5% | 0.05% | -36.1% |
| Q1 2023 | $24,084 | -26.7% | 2,887,739 | +0.9% | 0.08% | -29.7% |
| Q4 2022 | $32,860 | -99.9% | 2,862,387 | +25.5% | 0.12% | +4.4% |
| Q3 2022 | $28,740,000 | +29.4% | 2,280,953 | +8.7% | 0.11% | +32.9% |
| Q2 2022 | $22,211,000 | -18.0% | 2,099,327 | +26.1% | 0.08% | -9.6% |
| Q1 2022 | $27,077,000 | +3.4% | 1,665,256 | -11.9% | 0.09% | +6.8% |
| Q4 2021 | $26,193,000 | +13062.3% | 1,891,160 | +11482.3% | 0.09% | +4300.0% |
| Q4 2014 | $199,000 | – | 16,328 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VHCP Management, LLC | 1,744,356 | $18,455,000 | 9.59% |
| RA Capital Management | 4,347,456 | $45,996,000 | 3.30% |
| Cormorant Asset Management, LP | 1,168,000 | $12,357,000 | 2.84% |
| Baker Brothers Advisors | 5,867,031 | $62,073,000 | 0.79% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 907,920 | $9,606,000 | 0.39% |
| QVT Financial LP | 525,734 | $5,562,000 | 0.32% |
| EAM Investors, LLC | 114,548 | $1,212,000 | 0.22% |
| FRANKLIN STREET ADVISORS INC /NC | 93,000 | $984,000 | 0.20% |
| THB ASSET MANAGEMENT | 301,529 | $3,190,000 | 0.19% |
| TPG Group Holdings (SBS) Advisors, Inc. | 1,162,269 | $12,297,000 | 0.13% |